The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: DRUG: Standard Therapy
Sponsor: Shengjing Hospital